Emergent BioSolutions (EBS) Q3 2024 earnings summary

Executive summary

• Achieved critical stabilization milestones and entered the turnaround phase ahead of schedule, focusing on profitable growth and operational improvement.

• Q3 2024 revenues rose 9% year-over-year to $293.8M, with net income of $114.8M, a significant turnaround from a net loss of $263.4M in Q3 2023.

• Adjusted EBITDA for Q3 2024 surged to $105.3M (36% of revenues), up 432% year-over-year, reflecting operational improvements and cost controls.

• Completed $117M in asset sales, including RSDL® to SERB for $75M and Baltimore-Camden facility to Bora for $35M, supporting liquidity and debt reduction.

• Resolved legacy legal and compliance matters, including a $50M settlement from Janssen and preliminary approval of COVID securities litigation settlement.

Financial highlights

• Q3 2024 total revenues reached $293.8M, up 9% year-over-year; YTD revenues were $848.9M, up 10% versus prior year.

• Q3 2024 adjusted EBITDA was $105.3M, up from $19.8M in Q3 2023; YTD adjusted EBITDA reached $162.1M, up from $(25.7)M YTD 2023.

• Q3 2024 net income was $114.8M, compared to a net loss of $(263.4)M in Q3 2023; YTD net loss improved to $(159.3)M from $(711.0)M YTD 2023.

• Q3 2024 total segment adjusted gross margin was 59%, up from 38% in Q3 2023; gross margin for the nine months ended September 30, 2024, was 32%.

• Net cash provided by operating activities for the nine months was $138.6M, a $377M improvement over the prior year.

Outlook and guidance

• 2024 full-year revenue guidance raised to $1,065–$1,125M; adjusted EBITDA guidance increased to $180–$200M.

• Adjusted net loss for 2024 expected to be $(50)M to $(30)M; total segment adjusted gross margin forecasted at 43–45%.

• Management believes liquidity is sufficient to fund operations for at least the next twelve months, following asset sales and new credit agreements.

• Most MCM revenue for 2024 is already committed; commercial and MCM product sales expected at $420–430M and $510–550M, respectively.

• Quarterly results may vary due to timing of government contracts and product deliveries.